BIOSPAIN 2026

Want to tilt the odds in your favor on the roadshow? Hear it straight from the source: Spain’s top biotech VCs will unveil their investment playbooks—how they judge scientific risk, vet team credentials and experience, assess development plans, and prioritise therapeutic areas. Each investor gets a brisk, 9-minute spotlight to explain what truly moves the needle. Walk away with a sharper sense of how opportunities are valued and what to emphasize in your pitch.

Key success factors behind high-performing spin-offs, including team, science, funding strategy and execution. What to take into account in the early stages to move fast, de-risk projects and build strong foundations for growth. Insights and lessons learned from real cases and different stakeholder perspectives.

• Agnés Arbat (Oxolife) - Spanish biotech founder
• Gustavo Fuster (Hoffmann Eitle) - IP lawyer
• Etienne Drouet (IQVIA) – CRO (Regulatory and Clinical)
• Marcos Simón (CIC Biomagune) – Head of TTO

Companies seeking funding to develop treatments in neurology and oncology will present their companies and pitch their business opportunity.

Attendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2027.

---

• Ability Pharmaceuticals, SA  – Carles Domènech, CEO
• Innoup Farma Kinsy, S.l.  –  Elisa Longás, Chief Business Officer
• Labsinlove S.L. - Cristina Aguilera, CEO
• Lifesome Therapeutics, S.L.  – Ana Bouchet, CEO
• MIMO BIOSCIENCES  – Jessika Valero Gonzalez,. Business Development Director
• Nuage Therapeutics  – Andri Leonidou, Head Of Bi And Corporate Affairs
• Oncomatryx Biopharma SA  – Teresa Rodriguez-Carmona Garcia, Business Development Associate
• Peptomyc, S.l.  – Jesús Martín García, CEO
• Trimerbody Pharma  –  Marta Compte Grau, R&D Director

Spanish biotech spin-offs are stepping onto the global stage like nimble launchpads of innovation, pulling in investors and partners from Europe, the US and Asia. Rooted in world-class science yet built for translation, they marry academic brilliance with entrepreneurial grit — and with sharper international branding, smoother regulatory pathways and bolder cross-border alliances, they can turn local discoveries into scalable, globe-spanning solutions.

Build high-impact investor pitches that translate medical-device and in vitro diagnostics innovation into clear financial potential and patient-outcome narratives investors can’t ignore.

Attendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2027.

---

Debios Diagnostics — Joan Grasas, Ceo
Manina Medtech — Mónica, Rodríguez de la Vega Otazo, CEO
Opportunity Health — Germán Alejandro Sánchez Martín, CEO
Optec4Life — Francesc Paris Huguet, CEO

Bizkaia has developed its own model for promoting strategic sectors, based, on the one hand, on the territory's capacity to design and activate advanced tax instruments, and on the other hand, on the creation of new financing vehicles that combine private contributions or facilitate access to cutting-edge enabling technologies.

In this round table, representatives from the Bizkaia Provincial Treasury, Seed Capital Bizkaia, BEAZ, and Lank will share how the territory has built specific tools to accelerate innovation and generate new opportunities in sectors such as biotechnology, combining tax incentives, specialized public investment, and future-oriented technological strategies like BIQAIN.

Oscar Ugarte (director general de Seed Capital Bizkaia) *provisional
Valentín García (director de Innovación de Lantik) *provisional
Antonio Perez (Director General de Hacienda de Bizkaia)

Following a market correction, ATMPs are entering a more selective phase where scientific promise must be matched by clear execution. This session will examine what differentiates companies that get funded, scaled, and ultimately acquired. The discussion will focus on investor selection criteria at seed and Series A, including data thresholds, platform differentiation, and capital efficiency. It will also address the role of delivery and manufacturing in enabling—or limiting—scalability. From a pharma perspective, the panel will highlight what drives partnering and acquisition decisions, and why many ATMP companies fail to reach that stage. Bringing together investors, founders, pharma, and manufacturing experts, the session will provide a practical framework to assess ATMP opportunities in today’s environment.

• Regulatoria: AEMPS o alguna empresa experta en el tema (ej.: Asphalion o Clarek + Modet). TBC
• Legislación: un perfil que conozca la legislación y marco europeo (aquí sugeriríamos alguien de Vinces) TBC

5. Legislative perspective: VINCES???